These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39147820)

  • 1. Entinostat as a combinatorial therapeutic for rhabdomyosarcoma.
    Chauhan S; Lian E; Habib I; Liu Q; Anders NM; Bugg MM; Federman NC; Reid JM; Stewart CF; Cates T; Michalek JE; Keller C
    Sci Rep; 2024 Aug; 14(1):18936. PubMed ID: 39147820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
    Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
    Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
    Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
    Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
    Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
    Kurmasheva RT; Bandyopadhyay A; Favours E; Del Pozo V; Ghilu S; Phelps DA; Erickson SW; Peer CJ; Figg WD; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27820. PubMed ID: 31099166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
    Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
    Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2.
    Song Z; Gong B; Qu T; Chen Y; Zhao G; Jin Y; Zhao Q
    Biomed Pharmacother; 2024 Aug; 177():117126. PubMed ID: 38996706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lineage of origin in rhabdomyosarcoma informs pharmacological response.
    Abraham J; Nuñez-Álvarez Y; Hettmer S; Carrió E; Chen HI; Nishijo K; Huang ET; Prajapati SI; Walker RL; Davis S; Rebeles J; Wiebush H; McCleish AT; Hampton ST; Bjornson CR; Brack AS; Wagers AJ; Rando TA; Capecchi MR; Marini FC; Ehler BR; Zarzabal LA; Goros MW; Michalek JE; Meltzer PS; Langenau DM; LeGallo RD; Mansoor A; Chen Y; Suelves M; Rubin BP; Keller C
    Genes Dev; 2014 Jul; 28(14):1578-91. PubMed ID: 25030697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
    Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
    J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
    Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options.
    Brown RE; Buryanek J; Katz AM; Paz K; Wolff JE
    Oncotarget; 2016 Jul; 7(29):46263-46272. PubMed ID: 27323832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
    Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW
    Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.
    Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG
    Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
    Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
    Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.
    Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S
    Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
    Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
    Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.